leftspacer middlespacer rightspacer
About Menu
Featured Material


MAPS BULLETIN
MAPS Bulletin Spring 2014: Special Edition: Psychedelics and Education
 
About > Funding Priorities

Since our founding in 1986, MAPS has disbursed over $20 million to developing psychedelics and marijuana into prescription medicines for some of the most hard-to-treat illnesses and to educating the public honestly about the risks and benefits of these substances.

Every dollar has come from private donors committed to our mission. The pharmaceutical industry, government agencies that support research, and major foundations have not yet supported our work, so the continued expansion of psychedelic research still relies on the generosity of individual donors and family foundations.

Our top funding priorities are our studies of MDMA-assisted psychotherapy for chronic, treatment-resistant posttraumatic stress disorder (PTSD). These include our ongoing U.S. study in veterans, firefighters, and police officers; our ongoing U.S. Boulder/Intern study; and our studies in Israel and Canada. For more information, see below, visit our MDMA research page, download our Clinical Development Plan, or visit mdmaptsd.org.

Our other research projects include LSD-assisted psychotherapy for end-of-life anxiety and ibogaine therapy for drug addiction. Our study of smoked or vaporized marijuana for PTSD in veterans has approval from the FDA and an IRB, and was approved by the Department of Health and Human Services to purchase NIDA marijuana on March 14, 2014.

Donations can be restricted to specific projects or allocated to our general fund. Most of our funding needs are for research, but we also rely on your contributions for our educational mission and to maintain daily operations. MAPS sponsors research in both non-institutional and institutional settings; our Board of Directors has established a policy of limiting indirect overhead expenses for research in institutional settings to 10%.

We are also seeking bequests, in addition to gifts of cash, stock, real estate, art, and other goods (the four largest donations in MAPS' history have all been bequests). Learn more about including MAPS in your will or trust.

Donations to MAPS are tax-deductible for individuals residing in the United States. Tax deductions are also available through ally organizations for contributors in the United Kingdom (through the Beckley Foundation), Switzerland (through SaePT), Canada (through Tides Canada), and Israel (through Beer Yaakov Hospital). If you live outside the U.S. and would like your gift to be tax-deductible, please contact our office at .(JavaScript must be enabled to view this email address) or at (831) 429-MDMA (6362).

MDMA-Assisted Psychotherapy for PTSD Research Fund

Developing MDMA (3,4-methylenedioxymethamphetamine) into an FDA-approved prescription medicine for PTSD is our top funding priority. We are currently conducting or developing clinical trials of MDMA-assisted psychotherapy in the United States, Canada, Israel, and Switzerland.

To learn more about why MDMA-assisted psychotherapy holds such promise for PTSD patients, download one of our brochures or visit mdmaptsd.org.

We are preparing to move to Phase 3 of our drug development program, involving scores of therapists and hundreds of subjects possibly in multiple countries. The challenge is no longer convincing regulatory agencies of the value of this research, but finding the financial resources for conducting the Phase 3 studies required to make MDMA-assisted psychotherapy a legally available treatment for those who need it most. What are Phase 2 trials?

Our results have been promising: 83% of the subjects receiving MDMA-assisted psychotherapy in our flagship U.S. Phase 2 study no longer met the criteria for PTSD, and every patient who received a placebo and then went on to receive MDMA-assisted psychotherapy experienced significant and lasting improvements (published in July 2010 in the Journal of Psychopharmacology). A long-term follow-up of patients who received MDMA-assisted psychotherapy revealed that overall benefits were maintained an average of 3.8 years later (published January 2013 in the Journal of Psychopharmacology.

We currently have five Phase 2 studies initiated or in the approval process. The results from these studies will build on our prior results and help improve our treatment methodology. These improvements include developing our therapeutic model, training therapists to conduct Phase 2 and 3 studies, determining whether different causes of PTSD require different treatment methods, establishing an effective double-blind for our studies, discovering the size and variability of treatment effects, and determining how cultural differences affect treatment outcomes. Having the funds to complete our current Phase 2 studies is therefore of critical importance, not just for the patients involved but also for the future of psychedelic research worldwide.

Prominent media routinely feature our MDMA-assisted psychotherapy research program, including O: The Oprah Magazine, CNN, The Washington Post Magazine, The New York Times, The Boston Globe, and many more.

We Need Your Help to Complete Phase 2

We estimate that it will take $2.5 million and three years to be ready for our End-of-Phase 2 meeting with the FDA, and roughly $16 million and five years to complete Phase 3 and establish MDMA-assisted psychotherapy as a legally available treatment. Our current funding needs for Phase 2 clinical trials are:

Additional MDMA-Assisted Therapy Studies

Please donate today to help make MDMA-assisted psychotherapy a legal treatment.

Give Our Veterans Hope
1 in 7 Iraq and Afghanistan veterans suffer from PTSD, in many cases leading to suicide. We owe it to our veterans to stop this epidemic.

Tell the Pentagon to fund MAPS' groundbreaking work to treat PTSD.